Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02315599|
Recruitment Status : Recruiting
First Posted : December 12, 2014
Last Update Posted : June 11, 2020
- Gene therapy involves changing the genes inside the body s cells to stop disease. It is very closely regulated. People who have had this therapy may have problems months or even years later. Researchers do not know the long-term side effects, so they want to study people who have had the therapy. They want the study to continue over the next 15 years.
- To study over time the negative side effects from genetically engineered cellular therapy. This will be studied in people who have been in Pediatric Oncology Branch (POB) gene therapy trials.
- People who are currently or were previously in a research study with gene therapy in the National Cancer Institute POB.
- Participants blood will be tested right before they get the genetically changed cells. They will get the cells as part of another study.
- For the next year, they will come back to the clinic or see their doctor at home at least every 3 months. They will answer questions about their health and blood will be drawn.
- For the next 5 years, they will go to the clinic or see their own doctor once a year. They will have physical exam and blood will be drawn.
- For 10 years after that, they will be asked every year for health information.
- Participants will keep their contact information up to date with researchers. They may be phoned for more health information.
- If the participant was under 18 years old when given the gene therapy and turns 18 during this follow-up, they will be asked to sign a new consent form when they turn 18.
|Condition or disease|
|Pediatric Cancers Hematologic Malignancies Solid Tumors|
- Study subjects exposed to gene therapy interventions may be at risk for delayed or long term adverse consequences. The U.S. Food and Drug Administration (FDA) has issued Draft Guidance for Industry: Long Term Follow-up After Administration of Human Gene Therapy Products, which outlines a framework to assess the risk of gene therapy-related delayed adverse events and the essential elements appropriate for the conduct of long-term follow up observations.
- Accordingly some vector designs (i.e. use of an adenovirus), based on duration of persistence accompanied by cumulative preclinical and clinical evidence, may require shorter periods of observation than other vector designs (i.e. use of a lentivirus).
- To conduct long term safety evaluations after administration of genetically engineered cellular therapy to subjects who have participated in POB clinical trials.
-Subjects who have received at least one dose of a genetically engineered cellular therapy on a POB gene therapy clinical trial are eligible to participate.
- Subjects will be evaluated for long term safety and occurrence of adverse events according to the requirements established by the POB gene therapy parent protocol, the FDA guidance and the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines), to include:
Long term follow up after genetically engineered cellular therapy:
- Post-cell infusion evaluations for T-Cell persistence (if applicable)
- Monitoring for replication-competent retrovirus (RCR) or replication-competent lentivirus (RCL)
- For 5 years: Physical examination
- For 10 additional years: Complete Questionnaire
- To ensure adequate follow up for patients in POB receiving genetically engineered cellular therapy, a maximum accrual of 500 patients will be allowed on this study. To accommodate 15-year follow-up of all patients, this study will remain open until 2050
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials|
|Actual Study Start Date :||December 23, 2014|
|Estimated Primary Completion Date :||April 1, 2035|
|Estimated Study Completion Date :||August 1, 2050|
subjects who have participated in POB gene therapy clinical trials
- Conduct long term safety evaluations after gene therapy [ Time Frame: Every 3 months X 1 year then annually X 15 years ]PCR results (for RCR/RCL, gene transduced cells)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02315599
|Contact: Lauren Little||(240) email@example.com|
|Contact: John W Glod, M.D.||(240) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|Principal Investigator:||John W Glod, M.D.||National Cancer Institute (NCI)|